Annual Report 2021

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2021 153 The United Laboratories International Holdings Limited Annual Report 2021 Name of subsidiaries Place of incorporation/ establishment Issued and fully paid share capital/ registered capital Attributable equity interest held by the Company Principal activities and place of operation (Note a) 2021 2020 成都智匯城有限公司 (Note c) The PRC RMB10,000,000 100% 100% Investment holding in the PRC 聯邦制藥（中山）有限公司 (Note c) The PRC RMB50,000,000 100% 100% Inactive 聯邦生物科技（珠海橫琴）有限公司 (Note e) The PRC RMB100,000,000 100% N/A Research and development of pharmaceutical products in the PRC 珠海聯邦生物醫藥有限公司 (Note e) The PRC RMB100,000,000 100% N/A Research and development of pharmaceutical products in the PRC Notes: (a) Other than The United Laboratories (Hong Kong) Holding Limited, all subsidiaries are indirectly held by the Company. (b) A wholly foreign-owned enterprise established in the PRC. (c) A company established in the PRC with limited liability. (d) A joint stock limited liability company established in the PRC. (e) A company established in the PRC with limited liability during the year ended 31 December 2021. 44. LIST OF SUBSIDIARIES (Continued)